机械通气新生儿脑氧监测的效果:SafeBoosC-IIIv随机临床试验方案
SafeBoosC-IIIv是一项由研究者发起的国际多中心实用型III期随机临床试验,计划在16个国家60个新生儿重症监护病房纳入3000例胎龄>28+0周、生后<28天、预计需机械通气至少24小时的患儿,1:1随机分配至脑氧监测联合常规治疗组或常规治疗组。共同主要结局为校正年龄2岁时全因死亡或中重度神经发育障碍的复合结局,以及PARCA-R非言语认知评分。
要点
- 脑氧监测组在机械通气期间按SafeBoosC治疗指南管理,常规治疗组不进行脑氧监测。
- 共同主要结局为校正年龄2岁时死亡或中重度神经发育障碍复合结局及PARCA-R非言语认知评分。
- 计划纳入3000例,来自16个国家60个新生儿重症监护病房,1:1随机分配。
核心结论
- 需要一项随机临床试验来评估机械通气新生儿在常规治疗基础上加用脑氧监测的获益与危害。
研究设计与样本
- SafeBoosC-IIIv为研究者发起的国际多中心实用型III期随机临床试验,计划纳入3000例患儿,来自16个国家60个新生儿重症监护病房,按1:1分配至脑氧监测联合常规治疗组或常规治疗组。
主要发现
- 纳入标准为胎龄>28+0周、生后<28天、预计需机械通气至少24小时,并已获父母知情同意或采用延期同意或无退出机制。
- 排除标准为无可用脑氧监测仪、疑似或确诊脑损伤或脑病、或可能需手术的先天性心脏病。
- 脑氧监测组在新生儿重症监护病房机械通气期间接受脑氧监测,持续至治疗医生认为无用或至生后28天,并按SafeBoosC治疗指南治疗。
- 常规治疗组不接受脑氧监测,仅接受常规治疗。
- 共同主要结局为校正年龄2岁时全因死亡或中重度神经发育障碍的复合结局,以及校正年龄2岁时PARCA-R非言语认知评分。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The SafeBoosC project aims to test the clinical value of non-invasive cerebral oximetry by near-infrared spectroscopy in newborn infants. The purpose is to establish whether cerebral oximetry can be used to save newborn infants' lives and brains or not. Newborns contribute heavily to total childhood mortality and neonatal brain damage is the cause of a large part of handicaps such as cerebral palsy. The objective of the SafeBoosC-IIIv trial is to evaluate the benefits and harms of cerebral oximetry added to usual care versus usual care in mechanically ventilated newborns. METHODS/DESIGN: SafeBoosC-IIIv is an investigator-initiated, multinational, randomised, pragmatic phase-III clinical trial. The inclusion criteria will be newborns with a gestational age more than 28 + 0 weeks, postnatal age less than 28 days, predicted to require mechanical ventilation for at least 24 h, and prior informed consent from the parents or deferred consent or absence of opt-out. The exclusion criteria will be no available cerebral oximeter, suspicion of or confirmed brain injury or disorder, or congenital heart disease likely to require surgery. A total of 3000 participants will be randomised in 60 neonatal intensive care units from 16 countries, in a 1:1 allocation ratio to cerebral oximetry versus usual care. Participants in the cerebral oximetry group will undergo cerebral oximetry monitoring during mechanical ventilation in the neonatal intensive care unit for as long as deemed useful by the treating physician or until 28 days of life. The participants in the cerebral oximetry group will be treated according to the SafeBoosC treatment guideline. Participants in the usual care group will not receive cerebral oximetry and will receive usual care. We use two co-primary outcomes: (1) a composite of death from any cause or moderate to severe neurodevelopmental disability at 2 years of corrected age and (2) the non-verbal cognitive score of the Parent Report of Children's Abilities-Revised (PARCA-R) at 2 years of corrected age. DISCUSSION: There is need for a randomised clinical trial to evaluate cerebral oximetry added to usual care versus usual care in mechanically ventilated newborns. TRIAL REGISTRATION: The protocol is registered at www. CLINICALTRIALS: gov (NCT05907317; registered 18 June 2023).
引用
- Vestager ML, Hansen ML, Rasmussen MI, et al. The effects of cerebral oximetry in mechanically ventilated newborns: a protocol for the SafeBoosC-IIIv randomised clinical trial. Trials. 2023. PMID: 37898759. doi:10.1186/s13063-023-07699-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。